The University of Texas MD Anderson Cancer Center entered into an asset purchase agreement to acquire certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM) for $15 million on January 17, 2020. The purchase price of $15 million is payable in cash upon closing, less $1.5 million to be held in escrow for up to 18 months after the closing of the transaction. Under the transaction, The University of Texas MD Anderson Cancer Center will acquire approximately 60,000-square-foot Houston facility, including manufacturing, office and laboratory space. Approximately 35 employees currently employed at the facility will be employed by MD Anderson. The transaction is subject to approval of the Board of Regents of the University of Texas System, the entry into a master services agreement between Bellicum and The University of Texas MD Anderson Cancer Center, completion of an on-site inspection of the facility by certain regulatory entities, Bellicum obtaining consent from the landlord of the facility, and the satisfaction of customary terms and conditions, including adjustment to the purchase price. The transaction is expected to close on or before February 21, 2020. As of March 12, 2020, the closing of the transaction is expected to occur on or before March 31, 2020. Andrew L. Strong of Pillsbury Winthrop Shaw Pittman LLP acted as legal advisor to Bellicum and Roger Griesmeyer of Hunton Andrews Kurth LLP acted as legal advisor to The University of Texas MD Anderson Cancer Center.